{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:15:12Z","timestamp":1757610912999,"version":"3.44.0"},"reference-count":25,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,6,26]]},"published-print":{"date-parts":[[2025,9]]},"DOI":"10.2967\/jnumed.125.269729","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T14:45:10Z","timestamp":1753973110000},"page":"1385-1391","source":"Crossref","is-referenced-by-count":0,"title":["Assessing Interlesional Tumor Response and Patient Outcomes with Sequential PSMA PET\/CT in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.2967","volume":"66","author":[{"given":"Chlo\u00e9 S.","family":"Denis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bram","family":"De Laere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Vanwelkenhuyzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Hustinx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brieuc R.","family":"Sautois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Withofs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"2025090310401696000_66.9.1385.1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.urology.2017.04.062","article-title":"Predicting response and recognizing resistance: improving outcomes in patients with castration-resistant prostate cancer","volume":"109","author":"Shore","year":"2017","journal-title":"Urology."},{"key":"2025090310401696000_66.9.1385.2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.eururo.2024.09.008","article-title":"Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review","volume":"87","author":"Francini","year":"2025","journal-title":"Eur Urol."},{"key":"2025090310401696000_66.9.1385.3","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","article-title":"Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study","volume":"25","author":"Karpinski","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025090310401696000_66.9.1385.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265874"},{"key":"2025090310401696000_66.9.1385.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264964"},{"key":"2025090310401696000_66.9.1385.6","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.3390\/cancers14071770","article-title":"PSMA and choline PET for the assessment of response to therapy and survival outcomes in prostate cancer patients: a systematic review from the literature","volume":"14","author":"Alongi","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2025090310401696000_66.9.1385.7","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025090310401696000_66.9.1385.8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025090310401696000_66.9.1385.9","doi-asserted-by":"crossref","first-page":"e222148","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology."},{"key":"2025090310401696000_66.9.1385.10","doi-asserted-by":"crossref","first-page":"17588359241258367","DOI":"10.1177\/17588359241258367","article-title":"Treatment response assessment in mCRPC: is PSMA-PET\/CT going to take the lead?","volume":"16","author":"Di Franco","year":"2024","journal-title":"Ther Adv Med Oncol."},{"key":"2025090310401696000_66.9.1385.11","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.7150\/thno.96738","article-title":"PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: is there value beyond localization of disease?","volume":"14","author":"K\u00fcper","year":"2024","journal-title":"Theranostics."},{"key":"2025090310401696000_66.9.1385.12","first-page":"660","article-title":"Reduced segmentation of lesions is comparable to whole-body segmentation for response assessment by PSMA PET\/CT: initial experience with the keyhole approach","volume":"11","author":"Hartrampf","year":"2022","journal-title":"Biology (Basel)."},{"key":"2025090310401696000_66.9.1385.13","doi-asserted-by":"crossref","first-page":"102155","DOI":"10.1016\/j.clgc.2024.102155","article-title":"Assessing the heterogeneity of response of [68Ga] Ga-PSMA-11 PET\/CT lesions in patients with biochemical recurrence of prostate cancer","volume":"22","author":"Dell\u2019Oro","year":"2024","journal-title":"Clin Genitourin Cancer."},{"key":"2025090310401696000_66.9.1385.14","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.medj.2024.07.020","article-title":"Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer","volume":"5","author":"Pan","year":"2024","journal-title":"Med."},{"key":"2025090310401696000_66.9.1385.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2025090310401696000_66.9.1385.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263611"},{"key":"2025090310401696000_66.9.1385.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223099"},{"key":"2025090310401696000_66.9.1385.18","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1007\/s00259-023-06123-5","article-title":"Heterogeneity of [68Ga]Ga-PSMA-11 PET\/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone response","volume":"50","author":"Pan","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025090310401696000_66.9.1385.19","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaoncol.2019.0869","article-title":"Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer","volume":"5","author":"De Laere","year":"2019","journal-title":"JAMA Oncol."},{"key":"2025090310401696000_66.9.1385.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1943"},{"key":"2025090310401696000_66.9.1385.21","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/21655979.2021.2016086","article-title":"Prostate-specific membrane antigen modulates the progression of prostate cancer by regulating the synthesis of arginine and proline and the expression of androgen receptors and Fos proto-oncogenes","volume":"13","author":"Hong","year":"2022","journal-title":"Bioengineered."},{"key":"2025090310401696000_66.9.1385.22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","article-title":"Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer","volume":"4","author":"Bakht","year":"2023","journal-title":"Nat Cancer."},{"key":"2025090310401696000_66.9.1385.23","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00432-021-03583-w","article-title":"Antihormone treatment differentially regulates PSA secretion, PSMA expression and 68Ga-PSMA uptake in LNCaP cells","volume":"147","author":"Mathy","year":"2021","journal-title":"J Cancer Res Clin Oncol."},{"key":"2025090310401696000_66.9.1385.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264962"},{"key":"2025090310401696000_66.9.1385.25","doi-asserted-by":"crossref","first-page":"111774","DOI":"10.1016\/j.ejrad.2024.111774","article-title":"PSMA PET\/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients","volume":"181","author":"Kleiburg","year":"2024","journal-title":"Eur J Radiol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T17:41:21Z","timestamp":1756921281000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,2]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.2967\/jnumed.125.269729"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269729","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"type":"print","value":"0161-5505"},{"type":"electronic","value":"2159-662X"}],"subject":[],"published":{"date-parts":[[2025,7,31]]}}}